转甲状腺素蛋白淀粉样变性的初始T1与细胞外容积
本研究评估心脏转甲状腺素蛋白淀粉样变性(ATTR)中初始心肌T1的预后价值,并与细胞外容积(ECV)比较诊断准确性和预后。134例ATTRwt、81例ATTRm、44例肥厚型心肌病和12例无症状突变携带者接受心脏磁共振T1 mapping和ECV测量。初始T1和ECV在ATTR中均升高且诊断准确率高(T1 AUC 0.87,ECV AUC 0.91),两者均预测死亡,但仅ECV在调整后保持独立预后预测价值。
要点
- 初始T1和ECV在ATTR中均升高,诊断ATTR的AUC分别为0.87和0.91。
- ATTRwt与ATTRm之间初始T1和ECV无显著差异,ECV与99mTc-DPD闪烁显像相关性良好。
- 初始T1和ECV均预测死亡,但仅ECV在调整后保持独立预后预测价值。
核心结论
- 初始T1 mapping和ECV是诊断心脏ATTR的良好技术且与预后相关;两者均与死亡率相关,但仅ECV保持独立预后预测价值,提示ECV是心脏ATTR更稳健的标志物。
研究设计与样本
- 研究纳入134例ATTRwt(122例男性,年龄76±7岁)、81例ATTRm(60例男性,年龄69±11岁)、44例肥厚型心肌病(32例男性,年龄51±13岁)和12例无症状突变携带者(4例男性,年龄47±10岁);所有受试者接受心脏磁共振T1 mapping和ECV测量,ATTR患者还接受99mTc-DPD闪烁显像。
诊断标准与关键数值
- 初始T1诊断ATTR的AUC为0.87(95%CI:0.82至0.91),ECV诊断ATTR的AUC为0.91(95%CI:0.87至0.94);初始T1每增加59 ms的HR为1.225(95%CI:1.010至1.486,p<0.05),ECV每增加3%的HR为1.155(95%CI:1.097至1.216,p<0.001)。
临床应用与阅片要点
- 作者认为初始T1 mapping和ECV是诊断心脏ATTR的良好技术且与预后相关,但仅ECV在调整后保持独立预后预测价值,提示ECV是心脏ATTR更稳健的标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study evaluated the prognostic potential of native myocardial T1 in cardiac transthyretin amyloidosis (ATTR) and compared native T1 with extracellular volume (ECV) in terms of diagnostic accuracy and prognosis.
BACKGROUND: ATTR is an increasingly recognized cause of heart failure that has an overlapping clinical phenotype with hypertrophic cardiomyopathy (HCM). Native T1 mapping by cardiac magnetic resonance (CMR) is useful for diagnosis in cardiac amyloidosis but its prognostic potential has never been assessed.
METHODS: A total of 134 patients with wild-type ATTR (ATTRwt) (122 men; age 76 ± 7 years), 81 patients with hereditary-type ATTR (ATTRm) (60 men; age 69 ± 11 years), 44 patients with HCM (32 men; age 51 ± 13 years), and 12 asymptomatic mutation carriers (4 men; age 47 ± 10 years) were studied. All subjects underwent CMR with T1 mapping and ECV measurement. ATTR patients also underwent 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy.
RESULTS: Native T1 and ECV were elevated in ATTR compared with HCM (p < 0.001) and were both associated with a high diagnostic accuracy (area under the curve [AUC]: 0.87; 95% confidence interval [CI]: 0.82 to 0.91) for T1 and an AUC of 0.91 (95% CI: 0.87 to 0.94) for ECV. No significant difference in native T1 and ECV was found between ATTRwt and ATTRm, and ECV correlated well with 99mTc-DPD scintigraphy. During follow-up of a mean of 32 ± 17 months, 55 ATTRwt and 40 ATTRm patients died. Native T1 and ECV predicted death (T1: hazard ratio [HR]: 1.225 for each 59-ms increase; 95% CI: 1.010 to 1.486; p < 0.05; ECV: HR: 1.155 for each 3% increase; 95% CI: 1.097 to 1.216; p < 0.001), but only ECV remained independently predictive after adjustment for age, N-terminal pro-B-type natriuretic peptide, left ventricular ejection fraction, E/E', left ventricular mass index, DPD grade, and late gadolinium enhancement.
CONCLUSIONS: Native T1 mapping and ECV are good diagnostic techniques for cardiac ATTR that are associated with prognosis. Both parameters correlated with mortality, but only ECV remained independently predictive of prognosis, suggesting that it is a more robust marker in cardiac ATTR.
引用
- Martinez-Naharro A, Kotecha T, Norrington K, et al. Native T1 and Extracellular Volume in Transthyretin Amyloidosis. JACC Cardiovasc Imaging. 2018. PMID: 29550324. doi:10.1016/j.jcmg.2018.02.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。